FLT3 Inhibitors in Acute Myeloid Leukemia

FMS related tyrosine kinase 3 (FLT3) is a frequently mutated receptor tyrosine kinase in Acute Myeloid Leukemia. Novel Tyrosine kinase inhibitors against FLT3 are currently in clinical trial. Discover the latest research on FLT3 Inhibitors in Acute Myeloid Leukemia here.

January 9, 2021

A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia

American Journal of Cancer Research
Yi ZhangJie Jin
December 6, 2020
Open Access

Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia

Cancer Discovery
Bhavana BhatnagarAnn-Kathrin Eisfeld
November 10, 2020

Importance of gene mutation analysis as prognostic factor of acute myeloid leukemia

[Rinshō ketsueki] The Japanese journal of clinical hematology
Hiroki Yamaguchi
January 14, 2021

Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukaemia

Cancer Discovery
Stefan BjelosevicRicky W Johnstone
November 25, 2020
Open Access

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era

Blood Research
Sujin ChoiHyoung Jin Kang
November 21, 2020
Case Report

Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Iku KamitaniShingo Yano
January 8, 2021
Open Access

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia

FEBS Open Bio
Rosa G Lopez-ReyesManuel S Rodriguez
December 16, 2020
Open Access

Hyperleukocytosis predicts inferior clinical outcome in pediatric acute myeloid leukemia

Hematology
Lu-Hong XuFeng-Ying Yang
November 11, 2020
Open Access

Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Hyo Jeong KimJiyeon Ahn
December 9, 2020

Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia

Leukemia & Lymphoma
Cosimo CumboFrancesco Albano
January 17, 2021
Open Access

Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines

Molecular & Cellular Proteomics : MCP
Carolien van AlphenConnie R Jimenez

Sign up to follow this feed and discover related papers.

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Bone Marrow Neoplasms

Bone Marrow Neoplasms are cancers that occur in the bone marrow. Discover the latest research on Bone Marrow Neoplasms here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

© 2021 Meta ULC. All rights reserved
/feed-previews/flt3-inhibitors-in-acute-myeloid/ccd0b246-8cd3-4e24-a248-3cd939e7a2cb